GT103 Antibody in Lung Cancer Trial
Author Information
Author(s): Clarke Jeffrey M., Simon George R., Mamdani Hirva, Gu Lin, Herndon James E. II, Stinchcombe Thomas E., Ready Neal, Crawford Jeffrey, Sonpavde Guru, Balevic Stephen, Nixon Andrew B., Campa Michael, Gottlin Elizabeth B., Li Huihua, Saxena Ruchi, He You Wen, Antonia Scott, Patz Edward F.
Primary Institution: Duke Cancer Institute, Durham, NC USA
Hypothesis
The antibody GT103 targets complement factor H to promote anti-cancer immunity in patients with refractory non-small cell lung cancer.
Conclusion
GT103 was found to be safe and well tolerated, with some patients achieving stable disease.
Supporting Evidence
- GT103 was well tolerated at all dose levels, including the highest doses.
- Stable disease was observed in 9 patients, representing a disease control rate of 29%.
- The median overall survival was 25.7 weeks.
Takeaway
Researchers tested a new antibody called GT103 in lung cancer patients, and while it didn't shrink tumors, it was safe and some patients had stable disease.
Methodology
A phase 1b dose escalation trial was conducted to assess the safety and tolerability of GT103 in patients with refractory non-small cell lung cancer.
Potential Biases
Selection bias may have occurred due to the heavily pretreated patient population.
Limitations
The study had a small sample size and was a single-arm trial without a control group.
Participant Demographics
Median age was 63 years, 61% male, 74% white, and 71% had ECOG performance status 1.
Statistical Information
Confidence Interval
95% CI, 19.1–30.6 for median overall survival
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website